Vor Biopharma Inc Ordinary Shares VOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
-
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
-
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Vor Bio To Participate in Upcoming September Conferences
-
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $19.34
- Day Range
- $18.00–19.45
- 52-Week Range
- $6.50–31.31
- Bid/Ask
- $17.10 / $19.08
- Shares Outstanding
- 59.16M
- Market Cap
- $1.07B
- Volume/Avg
- 735,159 / 964,440
Key Statistics
- Price/Earnings (Normalized)
- 0.38
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 76
- Website
- https://www.vorbio.com
Valuation
|
Metric
|
VOR
|
|---|---|
Price/Earnings (Normalized) | 0.38 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
VOR
Financial Strength
|
Metric
|
VOR
|
|---|---|
Quick Ratio | 18.78 |
Current Ratio | 19.15 |
Interest Coverage | — |
Quick Ratio
VOR
Profitability
|
Metric
|
VOR
|
|---|---|
Return on Assets (Normalized) | 15.11% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VOR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^MBgv@! | LOCK|Z#^^W | $127B | |||
| Moderna Inc
MRNA
| LOCK|LPT$@&% | LOCK|!!C | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>c!F#^ | LOCK|@xJ? | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Xm!>$b | LOCK|H^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Wr^lQr | LOCK|Z#N | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<FpZ?# | LOCK|<>Zj | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nfSD%&<< | LOCK|%Brc | $27B | |||
| Incyte Corp
INCY
| LOCK|G<&<HM | LOCK|%Hx | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|JPw&FG | LOCK|p@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|K$#nd<M | LOCK|#^Q | $14B |
United States